GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (XPAR:GNFT) » Definitions » DeferredTaxAndRevenue

Genfit (XPAR:GNFT) DeferredTaxAndRevenue : €6.10 Mil (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Genfit DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Genfit's current deferred tax and revenue for the quarter that ended in Jun. 2024 was €6.10 Mil.

Genfit DeferredTaxAndRevenue Historical Data

The historical data trend for Genfit's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit DeferredTaxAndRevenue Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.12 14.30 14.48 11.69

Genfit Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.48 11.24 - 11.69 6.10

Genfit DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Genfit's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.